NEW YORK (GenomeWeb News) – Novartis, Takeda, The Wellcome Trust, and Daiichi Sankyo have all joined an organized effort to develop and identify genetic markers that could be used to predict which patients may be at risk for experiencing dangerous adverse reactions to specific drugs.
 
The International Serious Adverse Events Consortium (SAEC), a non-profit group that initially launched a year ago, is a partnership between drug companies, the US Food and Drug Administration, and research institutes.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.